Literature DB >> 2784985

Clinical effectiveness of desmopressin in a case of acquired von Willebrand's syndrome associated with benign monoclonal gammopathy.

G Castaman1, F Rodeghiero, E Di Bona, M Ruggeri.   

Abstract

A case of acquired von Willebrand's syndrome (avWs) secondary to benign monoclonal gammopathy, is described, in which desmopressin (DDAVP) has proven effective repeatedly in preventing bleeding after tooth extraction. The laboratory pattern was similar to that of congenital type IA von Willebrand's disease. After DDAVP, prolonged bleeding time and factor VIII/von Willebrand factor activities were normalized. The disappearance rate of the elicited activities was similar to that observed in patients with congenital disease. This report adds to the scarce data concerning the haemostatic effectiveness of DDAVP in avWs and suggests that this agent might also be used in controlling or preventing bleeding in patients with the acquired disease, selected on the basis of their biological responsiveness to a test-infusion.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2784985     DOI: 10.1007/bf00320776

Source DB:  PubMed          Journal:  Blut        ISSN: 0006-5242


  17 in total

1.  von Willebrand factor abnormalities in two patients with uraemia.

Authors:  F Rodeghiero; G Castaman; R Lombardi; P M Mannucci
Journal:  Lancet       Date:  1988-10-29       Impact factor: 79.321

Review 2.  Desmopressin (DDAVP) for treatment of disorders of hemostasis.

Authors:  P M Mannucci
Journal:  Prog Hemost Thromb       Date:  1986

3.  Acquired von Willebrand's disease caused by a monoclonal antibody.

Authors:  O Zettervall; I M Nilsson
Journal:  Acta Med Scand       Date:  1978

4.  Studies of the pathophysiology of acquired von Willebrand's disease in seven patients with lymphoproliferative disorders or benign monoclonal gammopathies.

Authors:  P M Mannucci; R Lombardi; R Bader; M H Horellou; G Finazzi; C Besana; J Conard; M Samama
Journal:  Blood       Date:  1984-09       Impact factor: 22.113

5.  Von Willebrand factor multimer patterns in von Willebrand's disease.

Authors:  L W Hoyer; C R Rizza; E G Tuddenham; C A Carta; H Armitage; F Rotblat
Journal:  Br J Haematol       Date:  1983-11       Impact factor: 6.998

6.  Epidemiological investigation of the prevalence of von Willebrand's disease.

Authors:  F Rodeghiero; G Castaman; E Dini
Journal:  Blood       Date:  1987-02       Impact factor: 22.113

7.  Abnormal structure of von Willebrand factor in myeloproliferative syndrome is associated to either thrombotic or bleeding diathesis.

Authors:  M F López-Fernández; C López-Berges; R Martín; A Pardo; F J Ramos; J Batlle
Journal:  Thromb Haemost       Date:  1987-08-04       Impact factor: 5.249

8.  Unique multimeric pattern of von Willebrand factor in a patient with a benign monoclonal gammopathy.

Authors:  M F López-Fernández; C López-Berges; R Martín; J Nieto; F del Rio; A López-Borrasca; J Batlle
Journal:  Scand J Haematol       Date:  1986-03

9.  Acquired von Willebrand's disease in the myeloproliferative syndrome.

Authors:  U Budde; G Schaefer; N Mueller; H Egli; J Dent; Z Ruggeri; T Zimmerman
Journal:  Blood       Date:  1984-11       Impact factor: 22.113

10.  Acquired type II von Willebrand's disease: demonstration of a complexed inhibitor of the von Willebrand factor-platelet interaction and response to treatment.

Authors:  J Goudemand; B Samor; C Caron; B Jude; D Gosset; C Mazurier
Journal:  Br J Haematol       Date:  1988-02       Impact factor: 6.998

View more
  1 in total

Review 1.  Current management of von Willebrand's disease.

Authors:  G Castaman; F Rodeghiero
Journal:  Drugs       Date:  1995-10       Impact factor: 9.546

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.